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TSE Infectivity
The Nature of the Prion 
The TSE Infectious Agent
TSE diseases (also known as Prion dis-
eases) are fatal infectious neurodegener-
ative diseases of animals which include 
Creutzfeldt-Jakob Disease (CJD) in hu-
mans, scrapie in sheep and goats, BSE in 
cattle, and Chronic Wasting disease 
(CWD) in deer. The true nature of the 
TSE infectious agent is unknown but it 
has been proposed that the agent is com-
posed solely of a misfolded form of the 
host prion protein, PrP. This abnormal 
form (PrPSc) is resistant to digestion with 
proteinase K (PK), is deposited in infected 
tissue, and co-purifies with infectivity. 
For these reasons, all current Rapid TSE 
Diagnostic assays are based on the de-
tection of PrPSc either by its PK resis-
tance, its altered conformation, or its af-
finity for specific ligands. Current tests 
can only be performed on post-mortem 
tissue, but new pre-mortem tests in de-
velopment are also based on the detec-
tion of PrPSc in accessible tissues and 
body fluids (such as blood) by amplifying 
or concentrating the low levels of PrPSc 
which may be present. 
All of these assays rely on the assump-
tion that the correlation between TSE in-
fectivity and PrPSc is always 100 %. How-
ever if disease can exist in the absence of 
large amounts of PrPSc, reliance on PK-
resistant PrP as a sole measure of infec-
tivity may in some instances underesti-
mate the biological properties of 
diagnostic samples, and undermine cur-
rent efforts to contain or eradicate TSEs.
Does PK-resistant PrP Correlate  
with Infectivity?
In our laboratory, transgenic mice which 
have a single amino acid mutation in the 
endogenous PrP gene (P101L) were inocu-
lated intracerebrally with TSE infectivity 
from a case of human familial prion dis-
ease (Gerstmann-Straussler-Scheinker 
disease; GSS) or a strain of scrapie propa-
gated in hamsters (263K). These mice (Tg 
101LL) developed clinical signs of TSE dis-
ease and also showed classical TSE asso-
ciated spongiform degeneration of the 
brain on post-mortem examination. How-
ever they contained extremely low or un-
detectable levels of PK-resistant PrP in the 
brain [1]. The lack of PrPSc would suggest 
that these tissues were not infectious, 
however disease could be transmitted very 
efficiently from these tissues to Tg 101LL 
and wild type mice. We performed further 
analyses of these tissues to determine the 
exact levels of the infectious agent and 
PrPSc that were present, and compared 
these with a well characterised laboratory 
strain of TSE agent, ME7. In 4 of 5 tissues 
examined the titres of infectivity were 
equivalent to or higher than ME7, but the 
levels of PK-resistant PrP were undetect-
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able by standard assay, and therefore esti-
mated to be less than 1 % of that seen in 
ME7. These data implied that either the 
number of PrPSc molecules per unit of in-
fectivity varies by over 1000-fold between 
strains, or that most PrPSc seen in end 
stage disease is not infectious.
Is PK-sensitive PrPSc  
the Infectious Agent?
Analyses of other PrP transgenic models 
with the 101L mutation have revealed 
the presence of an abnormal, disease as-
sociated conformer of PrP which appears 
to be sensitive to PK [2, 3]. It has been 
suggested that such PK-sensitive PrPSc 
(sPrPSc) conformers may be responsible 
for the observed high levels of TSE infec-
tivity in tissues containing no PK-resis-
tant PrP. We analysed tissues from our 
mice showing high titres of infectivity 
and low levels of PrPSc for the presence 
of sPrPSc by limited PK digestion studies, 
and immunoprecipitation studies using 
monoclonal antibodies specific for ab-
normal conformers of PrP. We found no 
evidence of sPrPSc in any of the tissues 
[1]. We also analysed these tissues using 
a Conformation Dependant Immunoas-
say (CDI) [4] which does not require PK 
digestion of samples to identify PrPSc. 
This assay measures the change in anti-
body binding following denaturation in 
guanidine. An increase in the denatured/
native ratio due to increased availability 
of an antibody epitope indicates the pres-
ence of abnormal PrP conformers. Again, 
this assay revealed no evidence of any 
abnormal PrP conformers in the high in-
fectivity/low PrPSc samples.
The 101L-PrP transgenic models in 
which sPrPSc is observed were created by 
a method which results in overexpression 
of the PrP transgene, and it is possible 
that the abnormal sPrPSc observed in 
these mice is produced in response to the 
8–16 fold overexpression of PrP in the 
mice. Our Tg 101LL line was produced by 
gene targeting, which introduces the mu-
tation into the endogenous murine PrP 
gene resulting in wild type expression of 
the mutated gene. The disease in Tg 
101LL mice is therefore due to infection of 
the mice with an exogenous TSE agent, 
implying that the conformers of abnormal 
PrP produced due to overexpression of 
PrP and TSE infection must be different.
Are All Abnormal Forms  
of PrP Infectious?
Our data indicate that the PrPSc observed 
in terminal disease tissues may be a 
pathological by-product of the infection 
rather than the infectious agent. Other 
studies have also reported transmission 
of disease from tissues containing no PK-
resistant PrP [5], indicating that this ob-
servation is not unique to the Tg 101LL 
line. In addition, following inoculation 
with an isolate of atypical human GSS we 
have shown the presence of PrP amyloid 
plaques in the brains of Tg 101LL mice 
which show no clinical signs of disease or 
spongiform degeneration in the brain [6]. 
The presence of PrP amyloid plaques in 
these apparently healthy mice implies 
that these amyloid deposits also do not 
contain the TSE infectious agent. 
The true nature of the TSE infectious 
agent is still the subject of much debate. 
Our data suggest that PK-resistant PrP, 
sPrPSc and PrP amyloid are not the in-
fectious agent, but it is possible that an 
as yet unidentified specific conformer of 
abnormal PrP holds the key to TSE in-
fectivity. However we cannot yet rule 
out the possible involvement of other 
molecules. 
Although our data suggest that PrPSc 
is not a marker of the TSE infectious 
agent, it is currently the best marker for 
diagnosis of TSE disease, and current 
testing is identifying and removing in-
fected animals from the food chain. How-
ever, it is vital that markers of TSE infec-
tivity other than PrPSc are identified and 
validated in models such as those we 
have described and characterised here. 
We anticipate that such research will 
lead to the development of more robust 
diagnostic assays for TSE disease which 
will have important implications for both 
animal and human health.
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Fig.: 1 Immunohistochemistry of sections from 101LL/263K infected brain, and control ME7 infected 
brain. Both tissues contain similar titres of the infectious agent (108.7 IU/g tissue), but 101LL/263K 
infected tissue contains < 1 % of the amount of PrPSc found in ME7 tissue.
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